Rimonabant is a selective CB1 receptor inverse agonist (Ki = 1.8 nM).1,2 It is an anorectic antiobesity drug originally approved for use in Europe but eventually withdrawn from the market because of potential severe psychiatric side effects.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten